Chase Leavitt Net Worth

The estimated Net Worth of Chase C. Leavitt is at least $692 Thousand dollars as of 12 April 2023. Mr. Leavitt owns over 25,000 units of Lineage Cell Therapeutics Inc stock worth over $92,491 and over the last 5 years he sold LCTX stock worth over $0. In addition, he makes $599,098 as General Counsel and Corporate Secretary at Lineage Cell Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Leavitt LCTX stock SEC Form 4 insiders trading

Chase has made over 4 trades of the Lineage Cell Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of LCTX stock worth $7,250 on 12 April 2023.

The largest trade he's ever made was buying 25,000 units of Lineage Cell Therapeutics Inc stock on 12 April 2023 worth over $7,250. On average, Chase trades about 2,813 units every 84 days since 2019. As of 12 April 2023 he still owns at least 106,901 units of Lineage Cell Therapeutics Inc stock.

You can see the complete history of Mr. Leavitt stock trades at the bottom of the page.

Chase Leavitt biography

Chase C. Leavitt J.D. serves as General Counsel and Corporate Secretary of the Company. Mr. Leavitt served as Vice President of Legal Affairs of Tang Capital Management, LLC, a life sciences-focused investment company, and its affiliate Odonate Therapeutics, Inc. (ODT), a publicly traded biotechnology company, from June 2018 to May 2019. From May 2017 to May 2018, Mr. Leavitt served as the Deputy General Counsel of Switch, Inc. (SWCH), a publicly traded technology company, and previously served as its Associate General Counsel from July 2014 to May 2017. From 2007 to 2014, Mr. Leavitt was a corporate attorney at Latham & Watkins LLP, where his practice focused on public company representation, mergers and acquisitions and capital markets, serving life sciences and technology companies. Mr. Leavitt received a B.S. degree in business administration and a J.D. from the University of Southern California and is admitted to practice law by the State Bar of California.

What is the salary of Chase Leavitt?

As the General Counsel and Corporate Secretary of Lineage Cell Therapeutics Inc, the total compensation of Chase Leavitt at Lineage Cell Therapeutics Inc is $599,098. There are 3 executives at Lineage Cell Therapeutics Inc getting paid more, with Brandi Roberts having the highest compensation of $947,963.

How old is Chase Leavitt?

Chase Leavitt is 38, he's been the General Counsel and Corporate Secretary of Lineage Cell Therapeutics Inc since 2019. There are 16 older and no younger executives at Lineage Cell Therapeutics Inc. The oldest executive at Lineage Cell Therapeutics Inc is Alfred Kingsley, 77, who is the Chairman of the Board.

What's Chase Leavitt's mailing address?

Chase's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 230, , SAN DIEGO, CA, 92130.

Insiders trading at Lineage Cell Therapeutics Inc

Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley, and Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.

What does Lineage Cell Therapeutics Inc do?

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Complete history of Mr. Leavitt stock trades at Lineage Cell Therapeutics Inc and Oncternal Therapeutics

Lineage Cell Therapeutics Inc executives and stock owners

Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include:

• Brandi Roberts,
  Chief Financial Officer
• Brian M. Culley M.A., M.B.A.,
  CEO, Pres & Director
• Brian Culley,
  Chief Executive Officer, Director
• Chase Leavitt,
  General Counsel and Corporate Secretary
• Brandi L. Roberts,
  Consultant
• Angus Russell,
  Independent Director
• Michael Mulroy,
  Independent Director
• Stephen Farrell,
  Independent Director
• Neal Bradsher,
  Independent Director
• Don Bailey,
  Independent Director
• Deborah Andrews,
  Independent Director
• Gary Hogge,
  Senior Vice President of Clinical & Medical Affairs
• Alfred Kingsley,
  Chairman of the Board
• Alexandra Hernandez,
  Sr. Director of Fin. & Controller
• Dr. Rami Skaliter,
  Chief Exec. Officer of Cell Cure Neurosciences Ltd.
• William Annett,
  Pres & CEO of OncoCyte Corp.
• Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.,
  Sr. VP of Clinical & Medical Affairs
• Dr. François Binette M.Sc., Ph.D.,
  Sr. VP & Global Head of R&D
• George A. Samuel III, J.D.,
  Gen. Counsel & Company Sec.
• Ioana C. Hone,
  Director of Investor Relations
• Kevin L. Cook,
  Chief Financial Officer
• George A. Iii Samuel,
  General Counsel/Secretary
• Anula Jayasuriya,
  
• Dipti Amin,
  
• Neal C Bradsher,
  Director
• Alexandra Hernandez,
  Sr Director Finance/Controller
• Kevin Leon Cook,
  Chief Financial Officer
• Jill Ann Howe,
  Chief Financial Officer